Balchem Corp. 10-Q Summary: Period Ended June 30, 2001
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Balchem Corporation for the period ended June 30, 2001. Balchem develops, manufactures, and markets specialty performance ingredients for food, feed, and medical sterilization industries. The company operates three segments: Specialty Products, Encapsulated/Nutritional Products, and a new Unencapsulated Feed Supplements segment established via a major acquisition in June 2001.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2001 | Six Months Ended June 30, 2000 |
|---|---|---|
| Net Sales | $18,213 (in thousands) | $15,600 (in thousands) |
| Gross Profit | $7,707 (in thousands) | $6,370 (in thousands) |
| Gross Margin | 42.3% | 40.8% |
| Net Earnings | $2,261 (in thousands) | $1,656 (in thousands) |
| Diluted EPS | $0.47 | $0.34 |
| Operating Cash Flow | $596 (in thousands) | $2,981 (in thousands) |
| Total Debt | $13,500 (in thousands) | $0 |
| Cash and Equivalents | $1,930 (in thousands) | $3,068 (in thousands) |
Material Changes vs. Prior Period
- Acquisition Impact: On June 1, 2001, the company acquired assets from DCV, Inc. and DuCoa L.P. for approximately $15.3 million. This created a new segment (Unencapsulated Feed Supplements) and significantly increased sales and assets.
- Revenue Growth: Net sales increased 17% year-over-year for the six-month period, driven by the acquisition and organic growth in the Encapsulated/Nutritional segment (up 26%).
- Debt Structure: The company moved from zero long-term debt to $13.5 million in debt to finance the acquisition. This includes a $13.5 million term loan maturing in 2009 and an unused $3.0 million revolving credit facility.
- Cash Flow Decline: Operating cash flow dropped significantly from $2.98 million to $0.60 million, primarily due to increased working capital requirements (inventory and receivables) associated with the new business.
- One-Time Income: The company recorded $324,000 in other income from the settlement of a class-action antitrust claim regarding vitamin products.
Guidance, Outlook, and Risks
- Capital Expenditures: Budgeted capital expenditures for the full year 2001 are approximately $1.8 million.
- Stock Repurchase: The board authorized an extension of the stock repurchase program for up to an additional 600,000 shares through June 30, 2002.
- Accounting Changes: The company must adopt SFAS No. 141 and No. 142 effective January 1, 2002. This will stop the amortization of goodwill and indefinite-life intangibles, replacing it with annual impairment testing. The company cannot currently estimate the financial impact of this transition.
- Market Risks: The company is exposed to interest rate risk on its variable-rate term loan (LIBOR + 1.25%). A 100 basis point increase would raise annual interest expense by approximately $135,000. Foreign currency and commodity price risks are deemed immaterial.
- Contingencies: The acquisition agreement includes potential earn-out payments of up to $3.0 million based on future gross margin performance of the acquired assets.
Investor Verification Checklist
- Verify the final purchase price allocation for the DCV/DuCoa acquisition, as the current $15.3 million figure is preliminary.
- Monitor the integration of the new Unencapsulated Feed Supplements segment, which currently reports a loss.
- Assess the impact of the new debt load ($13.5M) on future interest coverage ratios and cash flow.
- Review the upcoming adoption of SFAS 142 for potential goodwill impairment charges in 2002.
- Confirm the status of the $3.0 million contingent earn-out payments tied to the acquisition.